Photodynamic Therapy of Brain Tumours

  • Andrew H. Kaye


Cerebral tumours are responsible for approximately 2% of all cancer deaths and the high grade cerebral glioma is the most common cerebral tumour in adults. At the present time there is no satisfactory treatment for the malignant cerebral glioma. The best available treatment, using surgery, radiation therapy and systemic chemotherapy results in a median survival time of less than one year (Walker et al 1978; Walker et al 1980). In most cases surgery only provides a histological confirmation of the diagnosis and provides palliation of symptoms of raised intracranial pressure. Radiotherapy prolongs the median survival to 37 weeks and at present chemotherapy is of limited value when given by either conventional or the intracarotid route. Most treatment failures occur because of local recurrence of the tumour, indicating that a more aggressive local therapy to the tumour could be beneficial for the treatment of gliomas.


Photodynamic Therapy Malignant Brain Tumour Boron Neutron Capture Therapy Glioma Model Cerebral Tumour 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Daniell M and Hill J. History of photodynamic therapy. Australian and New Zealand Journal of Surgery, 1990 (in press).Google Scholar
  2. Diamond I, Granelli SG, McDonagh AF, Nielson S, Wilson CB and Janiecke R. Photodynamic therapy of malignant tumour. Lancet, 2: 1175–1177, 1972.PubMedCrossRefGoogle Scholar
  3. Kaye AH and Hill J. Photoradiation therapy of brain tumours; Laboratory and clinical studies. In Phototherapy of Cancer. Editors, Morstyn G and Kaye AH. Harwood Academic Publishers, New York, 101–118, 1990.Google Scholar
  4. Kaye AH and Morstyn G.Photoradiation therapy causing selective tumour kill in a rat glioma model. Neurosurgery, 20: 408–415, 1987.PubMedCrossRefGoogle Scholar
  5. Raye AH, Morstyn G and Apuzzo MLJ. Photoradiation therapy and its potential in the management of neurological tumours. J. Neurosurg., 69: 114, 1988.Google Scholar
  6. Kaye AH, Morstyn G and Ashcroft RG. Uptake and retention of haematoporphyrin derivative in an in vivo/in vitro model of cerebral glioma. Neurosurgery, 17: 883–890, 1985.PubMedCrossRefGoogle Scholar
  7. Kaye AH, Morstyn G and Brownbill D. Adjuvant high-dose photoradiation therapy in the treatment of cerebral glioma: a phase 1–2 study. J. Neurosurg., 67: 500–505, 1987.PubMedCrossRefGoogle Scholar
  8. Kaye AH, Morstyn G, Gardner I and Pyke K. Development of a xenograft glioma model in mouse brain. Cancer Res. 46: 1367–1373, 1986.PubMedGoogle Scholar
  9. Kostron H, Bellnier D-A, Lin C-W, Swartz MR and Martuza RL. Distribution retention and phototoxicity of haematoporphyrin derivative in a rat glioma:intraneoplastic versus intraperitoneal injection. J. Neurosurg. 64: 768–774, 1986.PubMedCrossRefGoogle Scholar
  10. Laws ER Jr., Cortese DA, Kinsey JH, Eagan RT and Anderson RE. Photoradiation therapy in the treatment of malignant brain tumours: a phase 1 (feasibility) study. Neurosurgery, 9: 672–678, 1981.PubMedCrossRefGoogle Scholar
  11. Lipson RL, Baldes EJ and Olsen AM. Haematoporphyrin derivative: a new aid for endoscopic detection of malignant disease. J. Thoracic. Cardiovasc. Burg. 42: 623–629, 1961.Google Scholar
  12. Lipson RL, Baldes EJ and Gray MJ. Haematoporphyrin derivative for detection and management of cancer. Cancer, 20: 2255–2257, 1967.PubMedCrossRefGoogle Scholar
  13. McCullough GAJ, Forbes IJ, Lee See K, Cowled PA, Facka FJ and Ward AD. Phototherapy in malignant brain tumours. In: Doiron DR, Gomer CJ, Eds. Porphyrin localisation and treatment of tumours New York, NY: Alan Liss Inc., 709–717, 1984.Google Scholar
  14. Muller PJ and Wilson BC. Photodynamic therapy, cavitary photoillumination of malignant cerebral tumours using a laser couples inflatable balloon. Canc. J. Neurol. Sci. 12: 371–373, 1985.Google Scholar
  15. Perria C. Photodynamic therapy in human gliomas by haematoporphyrin and He-Ne laser. IRCS Med. Sci. (Cancer), 9: 57–58, 1981.Google Scholar
  16. Walker MD, Alexander E Jr., Hunt WE, MacCarty C, Mahaley MS Jr., Mealey J Jr. et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: a co-operative clinical trial. J. Neurosurg. 49: 333–343, 1978.PubMedCrossRefGoogle Scholar
  17. Walker MD, Green SB, Byar DP, Alexander E Jr.,Batzdorf U, Brooks WH et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N. Engl. J. Med. 303: 1323–1229, 1980.PubMedCrossRefGoogle Scholar
  18. Wharen RE Jr., Anderson RE and Laws ER Jr. Quantitation of haematoporphyrin derivative in human gliomas, experimental central nervous system tumours, and normal tissues. Neurosurgery, 12: 446–450, 1986.CrossRefGoogle Scholar
  19. Wharen RJ Jr., So S, Anderson RE and Laws ER Jr. Haematoporphyrin derivative phototoxicity of human glioblastoma in cell culture. Neurosurgery, 12: 446–450, 1983.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1992

Authors and Affiliations

  • Andrew H. Kaye
    • 1
  1. 1.Higginbotham Neuroscience Research Institute, Departments of Surgery and NeurosurgeryRoyal Melbourne HospitalVictoriaAustralia

Personalised recommendations